Israeli startup to use AI to transform antibody discovery, design
Jerusalem Post
“The launch of CombinAble heralds a shift in the approach to targeted antibody design by leveraging AI to optimize and expedite the discovery process,” said Mati Gill, CEO of AION Labs.
https://www.jpost.com/business-and-innovation/article-792263